Johnson & Johnson raised its quarterly dividend by 3.1% to $1.34 per share, marking the company's 64th consecutive year of dividend increases. The healthcare giant reported second-quarter 2026 revenue of $25.3 billion, up 6.6% year over year, with adjusted EPS climbing 4.7% to $2.90 and free cash flow jumping to about $8.7 billion from $6.2 billion a year earlier. Management also raised its full-year outlook to approximately $101.1 billion in sales and adjusted EPS of $11.68, implying a payout ratio of roughly 46%. The company highlighted FDA approval of ICOTYDE, an oral peptide for plaque psoriasis and the first targeted oral peptide of its kind, as part of a pipeline that supports future dividend growth.
Johnson & JohnsonRaises dividend 3.1% and boosts full-year outlook, with strong Q2 results and free cash flow.
